anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fractures of the hyoid bone (HB) and thyroid cartilage (TC) are important findings in emergency medicine and forensic pathology. This study aimed to determine the occurrence and anatomical localization of HB and TC fractures and to evaluate the etiological and risk factors.A total of 315 patients with HB and/or TC fractures were included over a 3-year period. Data regarding the incident type, cause of death, age, sex, body mass index, regional trauma findings, location of fractures, resuscitation, and toxicological analyses were collected. Injury severity scores were calculated using the Abbreviated Injury Scale.The study found that HB and TC fractures were associated with trauma severity. The hanging cases exhibited the highest number of fractures. A significant association was observed between neck trauma localization and HB and TC fractures. Fractures of the HB and TC horns were more commonly associated with neck trauma than fractures of the corpus. Hyoid bone and TC fractures can occur without direct trauma, emphasizing the importance of thorough examination and diagnosis, particularly after cardiopulmonary resuscitation.This study provides valuable insights into HB and TC fractures and contributes to the understanding and identification of these fractures in forensic autopsies and clinical settings.
All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
Tobramycin inhalation solution, USP is a tobramycin solution for inhalation. It is a sterile, clear, colorless to slightly yellow, non-pyrogenic, aqueous solution with the pH and salinity adjusted specifically for administration by a compressed air driven reusable nebulizer. The chemical formula for tobramycin is C18H37N5O9 and the molecular weight is 467.52 g/mol. Tobramycin is O-3-amino-3-deoxy-α-D-glucopyranosyl-(1→4)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo hexopyranosyl-(1→6)]-2-deoxy-L-streptamine. The structural formula for tobramycin USP is:

Each single-dose 5 mL ampule contains 300 mg tobramycin, USP and 11.25 mg sodium chloride in sterile water for injection. Sulfuric acid and sodium hydroxide are added to adjust the pH to 6.0. Nitrogen is used for sparging. All ingredients meet USP requirements. The formulation contains no preservatives.
The present invention discloses multi-helix protein for inhibiting membrane virus infection, coding genes and application thereof. The multi-helix protein for inhibiting membrane virus infection, which is provided by the present invention, is trihelix protein or quinhelix protein formed by means that the repetitive sequences HR1 and HR2 of membrane virus I type fusion protein heptapeptide are connected by connecting peptide Linker 1 and Linker 2. The arrangement order of the trihelix protein is NH2HR1-Linker1-HR2-linker2-HR1COOH or NH2HR2-Linker2-HR1-linker1-HR2COOH. The arrangement order of the quinhelix protein is NH2HR1-Linker1-HR2-linker2-HR1-Linker1-HR2-linker2-HR1COOH. The connecting peptide Linker1 and Linker2 is polypeptide composed of 5 to 7 amino acid residues. Medicine with the multi-helix protein for inhibiting membrane virus infection and a derivative thereof as active components has important functions for preventing and/or treating membrane virus infection containing I type fusion protein.
Adverse event data were derived from 602 patients treated for systemic fungal disease in U.S. clinical trials who were immunocompromised or receiving multiple concomitant medications. Treatment was discontinued in 10.5% of patients due to adverse events. The median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). The table lists adverse events reported by at least 1% of patients.

Table 3: Clinical Trials of Systemic Fungal Infections: Adverse Events Occurring with an Incidence of Greater than or Equal to 1%

* Rash tends to occur more frequently in immunocompromised patients receiving immunosuppressive medications.

Adverse events infrequently reported in all studies included constipation, gastritis, depression, insomnia, tinnitus, menstrual disorder, adrenal insufficiency, gynecomastia, and male breast pain.
Dexmedetomidine \& Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
Thrombotic thrombocytopenic purpura (TTP) is a rare disease with a mortality rate of over 90% if left untreated \[1\]. TTP is a prototype of the thrombotic microangiopathies (TMAs), and it is characterized by disseminated formation of platelet-rich thrombi in arterioles and capillaries resulting in microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and potential end-organ injury mainly involving the brain, heart, and kidneys leading to significant morbidity/mortality. TTP can either be hereditary or acquired, and the pathogenesis of the latter consists of autoimmune antibodies against the metalloproteinase "a disintegrin and metalloproteinase with a thrombospondin type 1 motif (ADAMTS13)", and ADAMTS13 is responsible for the cleavage of ultra-large multimers of von Willebrand factor (vWF), which induces activation of platelets through glycoprotein Ib-alpha (GPIb-α) receptors and the activated A1 domain of the VWF multimers without a trigger-like endothelial damage or tissue factor. Acquired TTP (aTTP) can be primary (idiopathic) or secondary to some underlying disorders. Therapeutic plasma exchange (PEX) is the mainstay of treatment of aTTP, and with the introduction of PEX, the mortality rate declined dramatically below 20% \[1\]. The rationale of PEX is the replacement of ADAMTS13, and removal of ultra-large vWF and anti ADAMTS13 antibodies. In newly diagnosed patients with aTTP, PEX and corticosteroids are usually started upfront together \[3\]. However, a subset of patients may remain refractory to this treatment or have an initial response but relapse after the discontinuation of PEX during the follow-up. There is limited information or consensus available on the management of relapsed/refractory aTTP. While managing PEX refractory patients, PEX may be intensified to 1.5 plasma volume (PV), and even twice daily PEX can be used \[4\]. In patients remaining refractory to PEX plus corticosteroids, the administration of high-dose methylprednisolone 1 g per day for 3 days can be the choice of treatment \[5\].Other treatment options in patients with relapsed/refractory TTP may include rituximab, vincristine, cyclophosphamide, cyclosporine A, and splenectomy\[6-8\]. Caplacizumab is fully reimbursed by the National Health System in Italy since January 2020. While observational data have recently been published in other countries, such as Germany, on the efficacy and safety of caplacizumab \[18\], cumulative data deriving from the Italian centers that manage the therapy of TTP with caplacizumab have not yet been collected. The aim of this proposal is, therefore,to collect retrospective observationaldata on the response to caplacizumab treatment in patients with aTTP treated with this drug in Italy during the Q4-2019 and Q1-2021.
In South Africa, \>5 million people, including many adolescents, are living with HIV. Prevalence is increasing throughout South Africa, most precipitously in the Western Cape, the site of our proposed study. The investigators propose to pilot test a multisession worksite-based program to help parents learn how to take an active role in rearing sexually healthy youth. Our specific aims are to: (1) Culturally adapt our US-developed worksite-based program for parents of adolescents to the South African context; (2) Examine whether a worksite-based program for parents of adolescents in South Africa improves the parent-child relationship, including general parent-child communication and communication about sexual health and HIV risk-reduction, as perceived by parents and adolescents; (3) Explore program effects on parents' HIV testing and sexual behaviors; and (4) Explore program effects on theoretically important psychosocial mediators of behavior change (e.g., greater self-efficacy for refusing sex and using condoms, and more perceived disadvantages of unprotected sex). The proposed research is a unique opportunity to adapt and pilot test an innovative HIV prevention intervention that promotes the health of families in a culturally acceptable and sustainable setting.

The research is being conducted in three phases. In Phase 1, the investigators conducted formative qualitative interviews with South African community members who work with adolescents and parents, who work on HIV prevention, and who hold relevant positions at worksites. The investigators used this information from key community members to culturally adapt the program. In Phase 2, the investigators are conducting a process evaluation of one intervention group of 15 parents using qualitative debriefing interviews and quantitative data. In Phase 3, the current phase, the investigators aim to conduct a pilot intervention to refine the program even further and test the evaluation methods with 60 Xhosa and Afrikaans-speaking parents and their 11-15-year-old adolescents (who will participate in the evaluation but not the program). Their outcomes will be compared to a wait-list control group of 60 Xhosa and Afrikaans-speaking parents and their 11-15-year-old adolescents.
PROBLEM TO BE SOLVED: To provide an apoptosis inducer having a higher therapeutic effect, and a cancer therapeutic medicine.SOLUTION: An siRNA targeting a predetermined partial sequence of the Y box binding protein 1 gene induces apoptosis of vascular endothelial cells. The siRNA inhibits lumen formation by vascular endothelial cells. The siRNA inhibits angiogenesis and causes vascular regression. The siRNA can control abnormal angiogenesis in tumor sites and the like. The siRNA can destroy excessively formed blood vessels. Therefore, the siRNA has a higher therapeutic effect on intractable tumors and proliferative vascular diseases.
The invention relates to methods and pharmaceutical compositions for treating cancer in a subject in need thereof. The inventors show that Vγ9Vδ2 cells reserve a significant intracellular pool of PD-1 located in early endosomes, which is mobilized at the cell membrane after bisphosphonate activation. The inventors show that PD-1 is a major regulator of Vγ9Vδ2 T-cell homeostasis, similarly to BTLA, another member of the Ig superfamily, for which the inventors previously demonstrated a key role in the regulation of TCR-independent and TCR- dependent Vγ9Vδ2 T-cell proliferation. PD-1 and BTLA differ in their expression pattern in Vγ9Vδ2 T cells and interestingly, combined blockade with monoclonal antibodies synergizes to improve Vγ9Vδ2 T cell expansion compared to single receptor blockade. The inventors show that γδT cells infiltrate prostate tumors and overexpress PD-1, in addition to BTLA and other co-inhibitory molecules. Thus the upregulation of PD-1 intracellular pool appears as a possible mechanism of immune escape by tumor cells, that upregulate PD-L1 and HVEM, by interfering with γδT cell antitumor activity. The inventors show that PD-1 and BTLA blockade improves Vγ9Vδ2 T cell proliferation and antitumor functions toward tumor cells. The present invention highlight a new role for PD-1 and the potent combination with BTLA in the control of Vγ9Vδ2 cells. Thus, the invention relates to PD-1 antagonist in combination with BTLA antagonist and/or BTN3 agonist for use in the treatment of cancer.
Proteins and small molecules in urine (biomarkers) have been used to probe for kidney and systemic diseases for hundreds of years. Urine reportedly contains a type of molecule called microRNA (miRNAs) that regulate a large number of biological processes. Impaired function of miRNAs is now recognized in an increasing number of disease processes. In the search for new biomarkers, the regulatory function of miRNAs and the relative simplicity and precision of characterizing miRNAs, are potential advantages when compared to traditional biomarkers.

The aim of this pilot project is to assess the potential of urine miRNAs as biomarkers for characterizing patients with autosomal dominant polycystic kidney disease (ADPKD), the most prevalent inherited cause of kidney failure. Individuals with other causes of chronic kidney disease (e.g., diabetes, glomerulonephritis), who are matched for key characteristics (e.g. age, sex, level of kidney function) will serve as the control population. A technique for isolation of miRNAs from urine samples will be tailored for the specific needs of this project. Biochemical and computational analysis of small RNAs from these samples will provide urine miRNA profiles and key variability statistics that will be use to design follow-up projects involving patients with kidney disease.
PURPOSE: 3D visualization is an important part of learning anatomy with cadavers generally used to effectuate this. However, high cost, ethical considerations, and limited accessibility can often limit the suitability of cadavers as teaching tools. Anatomical 3D printed models offer an alternative tool for teaching gross anatomy due to their low cost and accessibility. This study aims to investigate if combing gamification with 3D printed models can enhance the learning experience and be effective for teaching anatomy.
METHODS: 3D printed models of the bones of the foot and ankle were generated, and 267 first-year medical students from 2 consecutive cohorts worked in groups to put it together as a puzzle. Participants completed a questionnaire regarding perceptions of 3D models and their knowledge of foot anatomy, before and after the session and were asked to provide comments.
RESULTS: Analysis of the responses showed a significant increase in the confidence of the learners in their anatomy knowledge and an increased appreciation of the role that 3D models have in enhancing the learning experience. After the session, there were many comments saying how enjoyable and engaging 3D models were.
CONCLUSION: Through the puzzle element of the session, the students were challenged mentally to work out the anatomical features of the foot and ankle. The combined elements of the puzzle and the features of the 3D model assembly made the activity fun and conducive to active learning. The possibility of having fun was not something the students had considered before the session.
An oligonucleotide inhibitor of tyrosinase gene expression comprising a sequence of 15-25 nucleotides including a specific 21 nucleotide sequence (SEQ ID NO:1) which hybridizes to the human tyrosinase gene by Hoogsteen pairing to form a triple helix structure, is new. An oligonucleotide inhibitor of tyrosinase gene expression comprising a sequence of 15-25 nucleotides including a specific 21 nucleotide sequence (SEQ ID NO:1) which hybridizes to the human tyrosinase gene by Hoogsteen pairing to form a triple helix structure, is new. Independent claims are included for: (1) a cosmetic or dermatological composition comprising the oligonucleotide inhibitor; and (2) cosmetic process of treatment for depigmentation or to bleach the skin or hair, comprising application of the composition on pigmented zone of the skin or pilous of hair and optional repetition of the operation until the appearance of depigmented effect. 5'-C*TTC*TC*TC*TTTTTC*C*TTTTTC*-3' sequence (SEQ ID No. 1), where C* is a 5-methyl-cytosine ACTIVITY : Dermatological. MECHANISM OF ACTION : Tyrosinase expression inhibitor. The ability of the oligonucleotide to inhibit the expression of human tyrosinase was tested using reverse transcriptase polymerase chain reaction. The results showed that the LNA oligonucleotide exhibited an inhibition of 49%.
* Do not use fentanyl transdermal system for a condition for which it was not prescribed.
  * Do not give fentanyl transdermal system to other people, even if they have the same symptoms you have. Fentanyl transdermal system can harm other people and even cause death. Sharing fentanyl transdermal system is against the law.



This Medication Guide summarizes the most important information about fentanyl transdermal system. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about fentanyl transdermal system that is written for doctors.

For questions about fentanyl transdermal system, please call Apotex Corp. at 1-888-333-6127, 9 A.M. to 5 P.M. Eastern Time, Monday through Friday. If this is a medical emergency, please call 911.
The COVID-19 disease (caused by SARS-CoV-2) predominantly affects the lungs causing a pneumonia which can become severe and lead to death via a severe inflammatory response in the lungs for which patients require admission to intensive care units (ICU) and artificial ventilation of their lungs. However, early reports from China have documented an element of injury to the heart present in up to 20% of patients. They have also documented patients who have died on ICU from heart injury rather than lung injury in COVID-19 positive patients. There are increasing numbers of reports of patients with COVID-19 having significant inflammation of the heart. What is not known is the prevalence of significant inflammation of the heart secondary to the SARS-CoV-2 and also what the significance of the injury to the heart shown in 20% of patients through blood tests really represents. That is to say is the injury significant to the outcome of the patient?

In order to investigate this, it is proposed to conduct a heart scan in COVID-19 positive patients in hospital to determine what form of heart injury is caused by the disease as well as determining it's prevalence and whether a heart scan helps in risk stratifying the patient in terms of outcome. If it is found that there is a significant amount of heart injury done by the SARS-CoV-2 and it can be determined this at an early stage with a heart scan it may be possible to start a more aggressive strategy for the patient's management in hospital to reduce the chance of death. Alternatively, if it is found that the incidence of heart injury is low and a heart scan makes no difference to the management of the patient, medical teams can be advised of this.
PENG Block will be performed at the end of the surgery. Patients will be administered tenoxicam (Tilcotil 20 mg flakon) 20 mg IV every 12 hours in the postoperative period. A patient controlled device prepared with 5 mg/ ml tramadol (100 mg-Contramal ® ampul) will be attached to all patients with a protocol included 10 mg bolus without infusion dose, 20 min lockout time and 4 hour limit. If the VAS score will be ≥ 4, 0,5 mg/kg-1 meperidine (Aldolan ampul 100 mg/2 ml) IV will be administered.
PROBLEM TO BE SOLVED: To obtain an antiinflammatory agent containing a specific compound, effective for lowering the formation and activity of a specific factor in tissue, useful as an agent for the prevention and treatment of diseases relating to the specific factor e.g. diabetic complications such as retinopathy or inflammatory diseases such as rheumatoid arthritis and having low side effect. SOLUTION: This agent contains a compound of the formula [R is a (substituted)hydrocarbon group, etc.; Y is CO, etc.; (m) is 0 or 1; (n) is 0-2; X is CH or N; A is a bond, etc.; Q is oxygen atom, etc.; R<1> is H, etc.; L and M are each H, etc.] or its salt and exerts its action through a TNF(tumor necrosis factor)-α suppressing effect. A preferable example of the compound of the formula is 5-[4-[2-(5-ethyl-2-pyridyl) ethoxylbenzyl]-2,4-thiazolidinedione and its salt is preferably hydrochloride, etc. It is preferably administered at about 2-20 mg/kg per dose and 1-3 doses per day in the case of oral administration to adult.
This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
AIMS: Data on safety outcomes of left atrial appendage occlusion (LAAO) in elderly patients are limited. This study aimed to compare the outcomes of LAAO between octogenarians (age 80-89) and nonagenarians (age ≥90) vs. younger patients (age ≤79).
METHODS AND RESULTS: We conducted a retrospective cohort study using the National Inpatient Sample database to identify patients hospitalized for LAAO from 2016 to 2020 and to compare in-hospital safety outcomes in octogenarians and nonagenarians vs. younger patients. The primary outcome was a composite of in-hospital all-cause mortality or stroke. Secondary outcomes included procedural complications, length of stay (LOS), and total costs. Outcomes were determined using logistic regression models. Among 84 140 patients hospitalized for LAAO, 32.9% were octogenarians, 2.8% were nonagenarians, and 64.3% were ≤79 years of age. Over the study period, the volume of LAAO increased in all age groups (all Ptrend < 0.01). After adjustment for clinical and demographic factors, octogenarians and nonagenarians had similar odds of in-hospital all-cause mortality or stroke [adjusted odds ratio (aOR) 1.41, 95% confidence interval (CI) 0.93-2.13 for octogenarians; aOR 1.69, 95% CI 0.67-3.92 for nonagenarians], cardiac tamponade, acute kidney injury, major bleeding, and blood transfusion, in addition to similar LOS and total costs compared with younger patients (all P > 0.05). However, octogenarians and nonagenarians had higher odds of vascular complications compared with younger patients (aOR 1.47, 95% CI 1.08-1.99 for octogenarians; aOR 1.60, 95% CI 1.18-2.97 for nonagenarians).
CONCLUSION: Octogenarians and nonagenarians undergoing LAAO have a similar safety profile compared with clinically similar younger patients except for higher odds of vascular complications.